Let us Find out more
Johnson & Johnson (JNJ) is a $515B market cap trading at 24.54 Price to earnings.
Over the last five years, the stock has given more than 30% of return.
Trading at 15 times its future profits. That's well below the healthcare average of 18.
JnJ also pays an attractive dividend yield of 2.9%.
Consistent performer in the stock market as well pays stable dividends
Long-term stability it offers investors with consistent dividend makes it attractive play
JnJ stock has now bounced from its 52-week low of $150 in March 2023.
The JnJ stock is trading above $165 in April 2023, this is the resistance level of the stock
Once it crossed that level it will start an upward journey to reach its 52-week high of $181 level.
JnJ stock may reach the $200 level by 2025.
Johnson & Johnson is one of the top healthcare companies in the world.
The company presence worldwide
Johnson & Johnson has been facing a legal battle over its talk products.
Once this hangover cleared the stock will march its north-ward journey.
Reported a loss of $68 million due to a $6.9 bn charge tied to its proposal of settling lawsuits.
Beating Analyst Expectation in terms of revenue and EPS
Reported revenues of $24.75 billion in the last reported quarter, representing a year-over-year change of +5.6%.
EPS of $2.68 for the same period compares with $2.67 a year ago. Analysts expected $2.50 per share of earnings
Offered $8.9 billion to settle all of its present and future talc litigation, considered a positive move
Continuously gaining market for some of its drugs, including Darzalex.
Completed a $16.6 billion acquisition of heart pump maker Abiomed that would help accelerate its MedTech business.
Planning to spin off its consumer health business in 2023 through an Initial public offering (IPO).
J&J aims to raise a $42.95 bln valuation for consumer health unit Kenvue.
Expected to close the legal battle soon.
Raised its guidance for the full year with adjusted earnings per share to come in between $10.60 and $10.70.
Consistent dividend payer of around $3 per share over the years.
JNJ stock has more room for growth.
Size of the Company, Strong Financial, rising EPS
Offered $8.9 billion to settle all of its present and future talc litigation, considered a positive move
Those are areas that should provide stable, long-term growth to the company.
Please comment if you would like to see it in different way